Medicone Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 10-12-2024
- Paid Up Capital ₹ 0.50 M
as on 10-12-2024
- Company Age 23 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.90 M
as on 10-12-2024
- Revenue 7.94%
(FY 2022)
- Profit -2945.91%
(FY 2022)
- Ebitda -164.75%
(FY 2022)
- Net Worth -293.32%
(FY 2022)
- Total Assets 64.20%
(FY 2022)
About Medicone Formulations
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.90 M.
Nalin Bansal, Sankalp Bansal, and Seema Bansal serve as directors at the Company.
- CIN/LLPIN
U24231DL2001PTC109768
- Company No.
109768
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2001
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Medicone Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sankalp Bansal  | Director | 30-Jun-2005 | Current |
| Nalin Bansal | Director | 22-Feb-2001 | Current |
| Seema Bansal | Director | 30-Jun-2009 | Current |
Financial Performance of Medicone Formulations.
Medicone Formulations Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.94% increase. The company also saw a substantial fall in profitability, with a 2945.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 293.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medicone Formulations?
In 2022, Medicone Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Innthink Technologies Private LimitedActive 9 years 10 monthsNalin Bansal, Sankalp Bansal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 30 Sep 2021 | ₹3.50 M | Open |
Others Creation Date: 13 Sep 2021 | ₹3.40 M | Open |
Punjab & Sind Bank Creation Date: 14 Feb 2011 | ₹1.00 M | Open |
How Many Employees Work at Medicone Formulations?
Unlock and access historical data on people associated with Medicone Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicone Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicone Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
